Letrozole is a non-steroidal aromatase inhibitor that lowers estrogen production. It is medically used primarily in hormone-receptor-positive breast cancer, particularly in postmenopausal patients.

The listed Letrozolexin presentation contains 2.5 mg letrozole per tablet and is supplied as 50 oral tablets. These product specifications are taken directly from the current GORoids listing.

Letrozole should be used only for an appropriate clinical indication under professional supervision. The exact manufacturer labeling, storage conditions, and regulatory information should be verified before publication.